Recent News

• 09.29.2025 - Apollomics Announces Completion of Filing of Appeal of Nasdaq Delisting Order
• 09.23.2025 - Apollomics Announces Receipt of Nasdaq Delisting Notification, and Will Appeal to Retain
• 04.03.2025 - Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
• 03.31.2025 - Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
• 12.20.2024 - Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Recent Filings

• 09.25.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.25.2025 - EX-99.1 EX-99.1
• 09.09.2025 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership
• 09.05.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 09.05.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.03.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.28.2025 - EX-99.1 EX-99.1
• 08.28.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.25.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.03.2025 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]